Selinexor has been shown to prolong progression-free survival in patients with TP53-mutant endometrial cancer.

Published Date: 02 Aug 2023

According to a study presented at the July 2023 meeting of the American Society for Clinical Oncology Plenary, maintenance therapy with selinexor offers long-lasting survival advantages for endometrial cancer with TP53 mutations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Positive Survival Data in Lung Cancer With Perioperative Therapy

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

4.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot